- call +1-201-465-4211
- email sales@mrinsights.biz
Duchenne muscular dystrophy (DMD) therapeutics helps treat genetic disorder caused due to absence of dystrophin, a protein in the body. The symptoms of the disease include weakness in the muscles of the hips, pelvic area, thighs, and shoulders, and later in the muscles of arms, legs, and trunk.
Scope of the Report:
This report studies the Duchenne Muscular Dystrophy Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Duchenne Muscular Dystrophy Therapeutics market by product type and applications/end industries.
Factors such as, increase in incidences of Duchenne muscular dystrophy and introduction of specific guidance for development for Duchenne muscular dystrophy drugs by FDA drive the market growth. However, fast track approval of these drugs by FDA and untapped growth opportunities in the emerging economies of Asia-Pacific and LAMEA are expected to fuel the market growth during the forecast period.
The global Duchenne Muscular Dystrophy Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Duchenne Muscular Dystrophy Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Bristol-Myers Squibb
FibroGen (U.S.)
Italfarmaco (Italy)
Marathon
NS Pharma (U.S.)
PTC Therapeutics (U.S.)
Pfizer
ReveraGen BioPharma (U.S.)
Santhera Pharmaceuticals (Switzerland)
Sarepta Therapeutics (U.S.)
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort
Market Segment by Applications, can be divided into
Hospitals
Clinics
Home Care Settings
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Duchenne Muscular Dystrophy Therapeutics Market Overview
1.1 Product Overview and Scope of Duchenne Muscular Dystrophy Therapeutics
1.2 Classification of Duchenne Muscular Dystrophy Therapeutics by Types
1.2.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Types in 2017
1.2.3 Pain Management Drugs
1.2.4 Corticosteroids
1.2.5 Prednisolone
1.2.6 Prednisone
1.2.7 Deflazacort
1.3 Global Duchenne Muscular Dystrophy Therapeutics Market by Application
1.3.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care Settings
1.4 Global Duchenne Muscular Dystrophy Therapeutics Market by Regions
1.4.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Duchenne Muscular Dystrophy Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Duchenne Muscular Dystrophy Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Duchenne Muscular Dystrophy Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Duchenne Muscular Dystrophy Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Duchenne Muscular Dystrophy Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Duchenne Muscular Dystrophy Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Bristol-Myers Squibb
2.1.1 Business Overview
2.1.2 Duchenne Muscular Dystrophy Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 FibroGen (U.S.)
2.2.1 Business Overview
2.2.2 Duchenne Muscular Dystrophy Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 FibroGen (U.S.) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Italfarmaco (Italy)
2.3.1 Business Overview
2.3.2 Duchenne Muscular Dystrophy Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Marathon
2.4.1 Business Overview
2.4.2 Duchenne Muscular Dystrophy Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 NS Pharma (U.S.)
2.5.1 Business Overview
2.5.2 Duchenne Muscular Dystrophy Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 NS Pharma (U.S.) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 PTC Therapeutics (U.S.)
2.6.1 Business Overview
2.6.2 Duchenne Muscular Dystrophy Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 PTC Therapeutics (U.S.) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Pfizer
2.7.1 Business Overview
2.7.2 Duchenne Muscular Dystrophy Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 ReveraGen BioPharma (U.S.)
2.8.1 Business Overview
2.8.2 Duchenne Muscular Dystrophy Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 ReveraGen BioPharma (U.S.) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.9 Santhera Pharmaceuticals (Switzerland)
2.9.1 Business Overview
2.9.2 Duchenne Muscular Dystrophy Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.10 Sarepta Therapeutics (U.S.)
2.10.1 Business Overview
2.10.2 Duchenne Muscular Dystrophy Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Sarepta Therapeutics (U.S.) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Duchenne Muscular Dystrophy Therapeutics Market Competition, by Players
3.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Duchenne Muscular Dystrophy Therapeutics Players Market Share
3.2.2 Top 10 Duchenne Muscular Dystrophy Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Regions
4.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue and Market Share by Regions
4.2 North America Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Duchenne Muscular Dystrophy Therapeutics Revenue by Countries
5.1 North America Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2013-2018)
5.2 USA Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Duchenne Muscular Dystrophy Therapeutics Revenue by Countries
6.1 Europe Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue by Countries
7.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2013-2018)
7.2 China Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Duchenne Muscular Dystrophy Therapeutics Revenue by Countries
8.1 South America Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Duchenne Muscular Dystrophy Therapeutics by Countries
9.1 Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Duchenne Muscular Dystrophy Therapeutics Market Segment by Type
10.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Type (2018-2023)
10.3 Pain Management Drugs Revenue Growth Rate (2013-2023)
10.4 Corticosteroids Revenue Growth Rate (2013-2023)
10.5 Prednisolone Revenue Growth Rate (2013-2023)
10.6 Prednisone Revenue Growth Rate (2013-2023)
10.7 Deflazacort Revenue Growth Rate (2013-2023)
11 Global Duchenne Muscular Dystrophy Therapeutics Market Segment by Application
11.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Duchenne Muscular Dystrophy Therapeutics Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Clinics Revenue Growth (2013-2018)
11.5 Home Care Settings Revenue Growth (2013-2018)
12 Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast (2018-2023)
12.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast (2018-2023)
12.2 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Duchenne Muscular Dystrophy Therapeutics Picture
Table Product Specifications of Duchenne Muscular Dystrophy Therapeutics
Table Global Duchenne Muscular Dystrophy Th
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
